By Sabela Ojea
Shares of Pfizer on Friday declined 3.5%, to $31.00, in after-hours trading after the company slashed its outlook for the year amid views for lower Covid-19 related revenue.
The healthcare giant said it now expects to end 2023 with an unexpected $9 billion drop in sales from its Covid-19 vaccine and anti-viral treatment Paxlovid.
…
Read the full article here
